Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2020-08-06 Capital/Financing Update
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Signs Exclusive Distribution Pact with ForDoz Pharma for 2 Complex Injectable Assets Under Development.
Capital/Financing Update Classification · 95% confidence The document is a press release dated August 6, 2020, announcing that Lupin Limited has entered into an exclusive distribution agreement with ForDoz Pharma Corp for two complex injectable assets. The content focuses on the business agreement and strategic partnership, with no financial statements, regulatory filings, or detailed financial data. It is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically covers material events or information. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial or governance report. It is a corporate announcement about a capital/business development. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-08-06 English
Lupin Signs Exclusive Distribution Pact with ForDoz Pharma for 2 Complex Injectable Assets Under Development.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an agreement between Lupin Limited and ForDoz Pharma Corp for exclusive marketing and distribution rights of pharmaceutical assets. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on a business development update rather than financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial analysis, nor is it a report or certification. The document is a corporate announcement about a strategic partnership and product distribution agreement, fitting the category of Capital/Financing Update (CAP) as it relates to business development and potential future revenue streams through exclusive rights agreements.
2020-08-06 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new exclusive distribution agreement between Lupin Limited and ForDoz Pharma Corp. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on the business development and partnership details rather than financial results, management changes, or regulatory filings. It does not contain financial statements, voting results, or executive compensation details. The document length is about 6,321 characters, which is typical for a press release. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant business agreement impacting the company's commercial operations and potential future revenue streams.
2020-08-06 English
Lupin's Alliance Partner Concord Receives U.S. FDA Approval for Mycophenolate Mofetil Tablets USP.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by the company in alliance with another firm. It is addressed to stock exchanges as a disclosure pursuant to a regulatory listing obligation (SEBI Regulation 30). The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (4173 characters) and it is clearly a disclosure announcement rather than a detailed report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and disclosures that do not fit other specific categories.
2020-08-06 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by the company in alliance with another firm. It is addressed to stock exchanges as a disclosure pursuant to a regulatory listing obligation (SEBI Regulation 30). The document is short (4168 characters) and primarily serves as a regulatory announcement of a business development event, not a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed report data. It is not an earnings release or annual/interim report. It is a regulatory disclosure announcement about a material event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-08-06 English
Lupin Launches Favipiravir Drug Covihalt® for Treatment of Mild to Moderate COVID-19.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Favipiravir under the brand name Covihalt) for treatment of COVID-19. It is addressed to stock exchanges and references a disclosure pursuant to SEBI regulations. The content is promotional and informative about a product launch, not a financial report, earnings release, or regulatory filing about financial performance or corporate governance. It does not contain financial statements, management discussion, or voting results. It is a typical corporate announcement or press release about a product launch, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-08-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.